Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Novartis:
Q4 Statement:
Biopharmaceuticals (which include biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 41% (cc) to USD 218 million.

This was the Q3 Statement:
Global sales of Biopharmaceuticals (which include biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 28% (cc) to USD 186 million, including continued progress of the newly launched Glatopa. Sandoz further strengthened its leading global position in biosimilars with the launch of Zarxio, the first biosimilar medicine approved under the new BPCIA pathway available in the US.


It looks like this groups sales increased $32 mil Q over Q with Glatopa and the new Biosimilar Zarxio (Neupogen).

Impressed? Nope.